These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8815696)

  • 1. Perspectives in HIV protease inhibitors.
    Leonard JM
    Adv Exp Med Biol; 1996; 394():319-25. PubMed ID: 8815696
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS drugs lurch towards market.
    Steele F
    Nat Med; 1995 Apr; 1(4):285-6. PubMed ID: 7585051
    [No Abstract]   [Full Text] [Related]  

  • 3. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
    Markowitz M; Mo H; Kempf DJ; Norbeck DW; Bhat TN; Erickson JW; Ho DD
    J Virol; 1995 Feb; 69(2):701-6. PubMed ID: 7815532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.
    Molla A; Korneyeva M; Gao Q; Vasavanonda S; Schipper PJ; Mo HM; Markowitz M; Chernyavskiy T; Niu P; Lyons N; Hsu A; Granneman GR; Ho DD; Boucher CA; Leonard JM; Norbeck DW; Kempf DJ
    Nat Med; 1996 Jul; 2(7):760-6. PubMed ID: 8673921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of HIV-1 protease.
    Meek TD
    J Enzyme Inhib; 1992; 6(1):65-98. PubMed ID: 1285304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
    Kempf DJ; Marsh KC; Denissen JF; McDonald E; Vasavanonda S; Flentge CA; Green BE; Fino L; Park CH; Kong XP
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2484-8. PubMed ID: 7708670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic binding of inhibitors to the protease from HIV type 1.
    Asante-Appiah E; Chan WW
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):113-7. PubMed ID: 8670094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conference looks at HIV drug resistance.
    Chang HE
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closing in on human immunodeficiency virus-1.
    Mellors JW
    Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219
    [No Abstract]   [Full Text] [Related]  

  • 10. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 11. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors: a tale of two companies.
    Cohen J
    Science; 1996 Jun; 272(5270):1882-3. PubMed ID: 8658156
    [No Abstract]   [Full Text] [Related]  

  • 13. Viral proteases as targets for chemotherapeutic intervention.
    Hellen CU; Wimmer E
    Curr Opin Biotechnol; 1992 Dec; 3(6):643-9. PubMed ID: 1369416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.
    Mekapati SB; Sivakumar R; Gupta SP
    J Enzyme Inhib; 2001; 16(3):185-97. PubMed ID: 11697040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
    Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A; Leonard JM
    N Engl J Med; 1995 Dec; 333(23):1534-9. PubMed ID: 7477168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [For the first time a combination of 2 protease inhibitors investigated].
    Schenk M
    Dtsch Med Wochenschr; 1996 Aug; 121(34-35):A36. PubMed ID: 8829900
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
    Kempf DJ; Marsh KC; Paul DA; Knigge MF; Norbeck DW; Kohlbrenner WE; Codacovi L; Vasavanonda S; Bryant P; Wang XC
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2209-14. PubMed ID: 1803993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
    Katzenstein D; Ogden R
    Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
    [No Abstract]   [Full Text] [Related]  

  • 19. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
    Danner SA; Carr A; Leonard JM; Lehman LM; Gudiol F; Gonzales J; Raventos A; Rubio R; Bouza E; Pintado V
    N Engl J Med; 1995 Dec; 333(23):1528-33. PubMed ID: 7477167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.